Target Name: MIR1229
NCBI ID: G100302156
Review Report on MIR1229 Target / Biomarker Content of Review Report on MIR1229 Target / Biomarker
MIR1229
Other Name(s): hsa-miR-1229-5p | hsa-mir-1229 | microRNA 1229 | MicroRNA 1229 | hsa-miR-1229-3p | MIRN1229

MIR1229: A Potential Drug Target and Biomarker for Cancer

Malignant tumors are one of the leading causes of cancer-related deaths worldwide. Despite advances in cancer treatment, the survival rate for many types of cancer remains poor. Therefore, there is a need for new treatments and approaches that can improve patient outcomes. One potential solution to this problem is the identification of drug targets and biomarkers that can be used to predict the effectiveness of cancer treatments. In this article, we will focus on MIR1229, a potential drug target and biomarker for cancer.

MIR1229 is a protein that is expressed in a variety of tissues and cell types, including the lungs, breast tissue, and ovarian tissue. It is a cytoplasmic protein that is associated with the mitochondria, which are the energy-producing structures in cells. MIR1229 has been shown to play a role in cell signaling, specifically in the regulation of cell growth and differentiation.

One of the key functions of MIR1229 is its role in the regulation of mitochondrial function. MIR1229 has been shown to interact with the protein known as p53, which is a well-known tumor suppressor protein. p53 is a transcription factor that plays a critical role in regulating gene expression and cell growth. By interacting with p53, MIR1229 has been shown to regulate the activity of p53, which in turn can lead to the inhibition of cell growth and the regulation of cell differentiation.

Another function of MIR1229 is its role in cell signaling. MIR1229 has been shown to interact with the protein known as TGF-β, which is a key regulator of cell growth and differentiation. TGF-β is a transmembrane protein that is involved in the regulation of cell signaling, including the regulation of cell growth and the inducement of apoptosis. By interacting with TGF-β, MIR1229 has been shown to regulate the activity of TGF-β, which in turn can lead to the regulation of cell growth and the inducement of apoptosis.

In addition to its role in cell signaling, MIR1229 has also been shown to play a role in the regulation of cellular processes such as cell adhesion and migration. MIR1229 has been shown to interact with the protein known as E-cadherin, which is a cell adhesion molecule that plays a critical role in the regulation of cell adhesion and migration. E-cadherin is a transmembrane protein that is involved in the regulation of cell adhesion and migration, including the regulation of cell migration and the inhibition of cell adhesion.

MIR1229 has also been shown to play a role in the regulation of cellular processes such as cell survival and apoptosis. MIR1229 has been shown to interact with the protein known as Bcl-2, which is a gene transcription factor that plays a critical role in the regulation of cell survival and apoptosis. Bcl-2 is a transmembrane protein that is involved in the regulation of cell survival and apoptosis, including the inhibition of cell apoptosis.

MIR1229 has been shown to play a role in the regulation of cellular processes such as cell signaling and cell adhesion and migration. It has also been shown to interact with a variety of other proteins, including p53, TGF-β, and Bcl-2. These interactions suggest that MIR1229 may be a potential drug target and biomarker for cancer.

In conclusion, MIR1229 is a protein that has been shown to play a role in

Protein Name: MicroRNA 1229

The "MIR1229 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR1229 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR1231 | MIR1233-1 | MIR1233-2 | MIR1234 | MIR1236 | MIR1237 | MIR1238 | MIR124-1 | MIR124-1HG | MIR124-2 | MIR124-2HG | MIR124-3 | MIR1243 | MIR1244-1 | MIR1244-2 | MIR1244-3 | MIR1245A | MIR1245B | MIR1246 | MIR1247 | MIR1248 | MIR1249 | MIR1250 | MIR1251 | MIR1252 | MIR1253 | MIR1254 | MIR1255A | MIR1255B1 | MIR1255B2 | MIR1256 | MIR1257 | MIR1258 | MIR125A | MIR125B1 | MIR125B2 | MIR126 | MIR1260A | MIR1260B | MIR1261 | MIR1262 | MIR1263 | MIR1264 | MIR1265 | MIR1266 | MIR1267 | MIR1268A | MIR1268B | MIR1269A | MIR1269B | MIR127 | MIR1270 | MIR1271 | MIR1272 | MIR1273A | MIR1273C | MIR1273H | MIR1275 | MIR1276 | MIR1277 | MIR1278 | MIR1279 | MIR128-1 | MIR128-2 | MIR1280 | MIR1281 | MIR1282 | MIR1283-1 | MIR1283-2 | MIR1284 | MIR1285-1 | MIR1285-2 | MIR1286 | MIR1287 | MIR1288 | MIR1289-1 | MIR1289-2 | MIR129-1 | MIR129-2 | MIR1290 | MIR1291 | MIR1292 | MIR1293 | MIR1294 | MIR1295A | MIR1295B | MIR1296 | MIR1297 | MIR1298 | MIR1299 | MIR1301 | MIR1302-1 | MIR1302-10 | MIR1302-11 | MIR1302-2 | MIR1302-3 | MIR1302-4 | MIR1302-5 | MIR1302-6 | MIR1302-7